Drug induces morphologic, molecular and clinical remissions in myelofibrosis

Imetelstat, a novel telomerase inhibiting drug, has been found to induce morphologic, molecular and clinical remissions in some patients with myelofibrosis a Mayo Clinic study has found. The results were presented today at the 2013 American Society of Hematology Annual Meeting in New Orleans.

"These are early results but they are promising, says the study's lead author, Ayalew Tefferi, M.D. a hematologist at Mayo Clinic. "Some in our clinical trial taking imetelstat obtained dramatic responses and there have been some complete responses which is almost unheard of for drug therapy in this disease."

Myelofibrosis is a chronic myeloid cancer in which that produce blood cells develop and function abnormally. The result is the formation of scar tissue in the bone marrow (fibrosis), severe anemia that often requires transfusion, weakness, fatigue and an enlarged spleen and liver. Patients with myelofibrosis harbor one of several genetic mutations in their , including JAK2, MPL, CALR, ASXL1 and spliceosome pathway mutations.

"Typically, is characterized by marrow scarring and although patients may derive symptomatic relief from other treatments such as ruxolitinib, they usually do not revert back to normal bone marrow," Dr. Tefferi says. "Some patients in our trial have reverted back to normal bone marrow."

Imetelstat works by inhibiting telomerase activity in tumor cells which leads to cell death.

Researchers studied imetelstat in 33 patients at Mayo Clinic and have now followed the first 22 patients for a minimum of six months. Among the 22, five patients achieved complete or partial remissions, including reversal of fibrosis in four of the five patients. Two of the five patients with complete or partial remission have also experienced complete molecular remissions. The overall response rate was 41 percent.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Stopping liver cancer in its tracks

41 minutes ago

A University of Tokyo research group has discovered that AIM (Apoptosis Inhibitor of Macrophage), a protein that plays a preventive role in obesity progression, can also prevent tumor development in mice ...

HHS releases 13th Report on Carcinogens

1 hour ago

Four substances have been added in the U.S. Department of Health and Human Services 13th Report on Carcinogens, a science-based document that identifies chemical, biological, and physical agents that are ...

Dog's epigenome gives clues to human cancer

3 hours ago

The bond between humans and dogs is strong and ancient. From being the protector of the first herds in a faithful pet, dogs and people share many aspects of life. The relationship between the two species ...

User comments